Monthly Archives: May 2016

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System

2017-05-16T21:29:57+00:00

REDWOOD CITY, Calif. – May 24, 2016 – C2 Therapeutics, a privately-held medical device company founded to improve methods of eradicating unwanted tissue in endoscopic applications, today announced new data from four separate clinical studies designed to assess the safety and efficacy of its C2 CryoBalloon™ Focal Ablation System (CbFAS). The data, which support the safety and efficacy of the company’s CbFAS, were presented at Digestive Disease Week (DDW) 2016, which is taking place May 21 – 24 in San Diego.

Click here to see full release.

C2 Therapeutics Announces Data from Four Studies Reinforcing the Safety and Efficacy of its C2 CryoBalloon™ Focal Ablation System 2017-05-16T21:29:57+00:00